NEW YORK (Reuters Health) – Treatment with fluvastatin causes a significant reduction in LDL cholesterol in patients with chronic renal insufficiency, researchers report in the January issue of the American Journal of Kidney Diseases.
Dr. Ola Samuelsson, of Sahlgrenska University Hospital, Goteborg, Sweden, and colleagues note that chronic renal insufficiency is associated with abnormalities affecting lipoproteins containing both apolipoprotein (apo) A and B. These aberrations appear atherogenic and may promote the progression of renal failure.
To determine whether treatment with fluvastatin might be helpful in these circumstances, the researchers conducted a double-blind, crossover study of 45 patients with moderate to advanced chronic renal insufficiency. None had nephrosis or diabetes.
During two 8 week-periods, the subjects were randomized to daily treatment with fluvastatin 40 mg or placebo.
Compared with placebo, fluvastatin prompted a significant reduction in LDL cholesterol, apo B, and lipoprotein B complex. This was also true of variables including total cholesterol, triglycerides, apo E and lipoprotein B. No changes were seen in HDL cholesterol or lipoprotein A.
The researchers conclude that fluvastatin is well tolerated and effective in reducing apo B-containing lipoprotein levels. However, they also point out that the clinical significance of these changes "remains to be established in future studies."